

January 18, 2019
Nihon Medi-Physics Co., Ltd.
Yantai Dongcheng Pharmaceutical Group Co., Ltd.

Nihon Medi-Physics and Yantai Dongcheng Pharmaceutical Group Announce Strategic Partnership for Enhancing Presence in Chinese Nuclear Medicine Market

Tokyo, Japan and Shandon, China– January 18, 2019. Nihon Medi-Physics Co., Ltd (NMP), a leading radiopharmaceutical company in Japan and Yantai Dongcheng Pharmaceutical Group Co., Ltd (YDP), a public pharmaceutical enterprise group with strong radiopharmaceutical business in China, announced today that they have signed an agreement for a strategic partnership to enter and enhance presence in Chinese nuclear medicine market.

Both parties will collaborate to commercialize NMP’s radiopharmaceutical products, which are already approved for clinical use in Japan, for launch in China. In addition, both parties will work together for the future business in China in relation to manufacturing technology including cyclotron operation and new drug development strategy, so that they can contribute to development of pharmaceutical industry, nuclear medicine field in particular, in China.

[Comment from Mr. Hisashi Shimoda, President of Nihon Medi-Physics Co., Ltd.]

We have been operating our business to contribute to healthcare in Japan, but from now on our commitment should be expanded to development of healthcare in Asia. In order to start our business operation in Asian countries, not only to supply our products but to transfer our product manufacturing techniques including production management and quality control as well, it is quite encouraging for us to enter into partnership with YDP, which already has extensive achievements in nuclear medicine field in China.

[Comment from **Mr. Shouyi You, Chairman of the Board**, Yantai Dongcheng Pharmaceutical Group Co., Ltd.]

Expanding product portfolio and international collaboration in drug development are critical factors to accelerate our nuclear medicine business in China. We are very pleased to enter into partnership with NMP, the market leader in radiopharmaceutical industry in Japan.

About Nihon Medi-Physics Co., LTD. (NMP)

NMP is a leading company for radiopharmaceuticals in Japan, with dedicated operation in R&D, manufacture and stable product supply. By capitalizing our technological capability and credence cultivated over the years through diagnostic nuclear medicine field, we aim the early realization of the innovative business beyond our existing business; “Realization of Theranostics,” “Utilization of digital technology” and “Becoming the leading company of nuclear medicine in Asia.” We will continue to create corporate value and contribute to society. Please visit our website for more information. <https://www.nmp.co.jp>

About Yantai Dongcheng Pharmaceutical Group Co., Ltd. (YDP)

Established in 1998 as Dongcheng Biochemicals Co.,Ltd, YDP went public in May 2012 and has developed into an enterprise group which combines pharmaceutical R&D, production, marketing and capital operation together across four business fields of biochemical API, chemical synthetic drugs, modern Chinese Medicines and nuclear medicine. Please visit our web site for more information. <http://www.dcb-group.com/home/>

Enquiries

Nihon Medi-Physics Co., Ltd.

Soichi Nakamura PHONE+81-3-5634-7006

EMAIL soichi_nakamura@nmp.co.jp

Yantai Dongcheng Pharmaceutical Group Co., Ltd.

Qinglin Liu PHONE +86-535-6391521

EMAIL qlliu@dcb-group.com